The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Open accessAbstract
To determine how long antibodies against Middle East respiratory syndrome coronavirus persist, we measured long-term antibody responses among persons serologically positive or indeterminate after a 2012 outbreak in Jordan.Antibodies, including neutralizing antibodies, were detectable in 6 (86%) of 7 persons for at least 34 months after the outbreak. M iddle East respiratory syndrome coronavirus (MERS-CoV) causes acute respiratory illness, which can progress rapidly to respiratory failure and death in ≈40% of persons with laboratory-confirmed cases.The first known cases of MERS-CoV occurred during an outbreak of severe acute respiratory infections in Zarqa, Jordan, during March-April 2012 (1).New cases and clusters of MERS-CoV infections continue to occur within the Arabian Peninsula, and the virus has been exported to other countries around the world.For 2 persons affected by the April 2012 outbreak, the cause of death remained unknown until late 2012, when retained samples produced positive MERS-CoV results according to reverse transcription PCR.In May 2013, we obtained serologic and epidemiologic data from 124 persons: the 2012 outbreak survivors, their exposed contacts, and their household members.In that investigation, we found another 7 persons with positive MERS-CoV results according to ELISA and confirmatory results by immunofluorescence assay (IFA), microneutralization assay, or both (1).Results were indeterminate for another 8 exposed persons, whose results were positive by only 1 of these serologic methods; these 8 persons were deemed MERS testnegative overall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duration of Antibody Responses after Severe Acute Respiratory Syndrome
Wu, L.-P., Wang, N.-C., Chang, Y.-H., Tian, X.-Y., Na, D.-Y., Zhang, L.-Y., Zheng, L., Lan, T., Wang, L.-F., & Liang, G.-D. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1310.070576 · Cited by 426 · cited 1×
“After SARS-CoV infection, robust IgG titers were observed through the second year but declined substantially during the third year after infection (10).”
Cited by
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Metadata
- Authors
- Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Al Nsour, M., Alsanouri, T., Ali, S. S., Harcourt, J., Miao, C., Tamin, A., Gerber, S. I., Haynes, L. M., & Al Abdallat, M. M.
- Venue
- Emerging Infectious Diseases
- Published
- 2016-10
- Volume
- 22
- Issue
- 10
- Pages
- 1824-1826
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2474518709
- Cited by
- 201
- References
- 1
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.